Custom Solutions & in silico Projects

Use our customized technology & expertise for informed decisions

Molecular medicine is a field in flux, with hospitals, research institutions and pharmaceutical companies of all kinds pushing the boundaries of what is possible on a daily basis. Molecular Health can help you achieve your goals faster by working with you to provide the kind of insights you need. Whether it is building a custom platform to let you explore your clinico-molecular data, or doing the investigation for you in silico, it all starts with a conversation.

Custom Solution

Use your EMR data to improve your healthcare delivery

EMR data holds great promise for the analysis of clinical pathways and outcomes. But generating insights is next to impossible with siloed departments, disparate databases, non-standardized vocabularies, and a combination of structured and unstructured data integration processes.

If your needs aren’t met by an existing platform, Molecular Health can leverage deep expertise in integrating patient and molecular data with ground-breaking automated and curated technologies to build a solution that will help you make sense of your data.

Request Demo

MH CUSTOM SOLUTION CAN HELP YOU DECIPHER YOUR DATA

Whether we are partnering with you to jumpstart the practice of Precision Medicine, improve workflow, optimize your care planning process, discover sources of wasteful spending, or develop new protocols specific to your patient demographics, we start with a high-level understanding of your data.

Once we are familiar with your data, we structure, clean, and integrate them with our Dataome™ knowledgebase, allowing you to derive clinical insights that are deep and far-reaching. These insights can be retrospective – to help identify areas or processes that can be improved across pre-defined KPIs; or they can be prospective – to provide caregivers with predictive result-oriented inferences that sharpen their clinical decision-making processes pre-emptively. Either way, an MH Custom Solution delivers exactly what you need because it is designed to solve your challenges.

Request Demo

INCORPORATE YOUR PATIENTS’ UNIQUE GENETIC CODE IN YOUR CARE DECISIONS

Interpreting clinico-molecular data for complex cases and acting on it to make informed therapeutic decisions can be challenging. Most existing drugs today translate to disease targets, not molecular pathways or biomarker signals. This is where Molecular Health can help. We have deep and broad technical and human expertise in making sense of molecular data which enables us to give your providers the powerful tools they need to help them make better decisions about complicated diseases with complicated molecular pathways . Let us create a solution for you that fits your process and is defined by your healthcare professionals.

Request Demo

in silico Projects

Leverage our technology and expertise for faster in silico research

The current method for discovery, development and commercializing drugs is long and expensive – and has been less successful over the last few decades, with increasing R&D costs and failure rates. But by working with Molecular Health on in silico projects, Pharma and Biotech companies can change the process into a fast-feedback loop that dramatically increases their chances of success.

Request Demo

LET US HELP YOU PREDICT DRUG RESPONSE AND RESISTANCE in silico

Machine learning and artificial intelligence can help Pharma and Biotech predict outcomes, but creating a good, reliable model can take time. Let Molecular Health be your shortcut. Give us your use case and we can apply our Dataome™ knowledgebase and analytics to help you address the hardest questions with the highest stakes in your drug translational and clinical development efforts.

Dataome is a technology platform that empowers the quality-controlled capture, integration and analysis of structured clinical and unstructured clinico-molecular data knowledge for millions of patients globally. Developed for over a decade, it represents a single-point of access to the current state of available biomedical knowledge. As data and knowledge grow, Dataome grows – providing the evidence-base required to make a data-driven difference in clinical discovery and patient care. We can generate meaningful insights that will help you predict drug safety and efficacy – the two major concerns for any development project.

Your project may take from a few days to a few months, depending on the complexity of the question and the data that needs to be interrogated to address it. But we can guarantee it will take much less time than starting disease and target models from scratch.

These are typical use cases we have been asked to address, and types of projects we can run for you.

 

Request Demo

See what you can do in silico

COHORT

THE PROBLEM

Immuno-oncology drugs are quickly gaining market share because of their superior and (relative to other targeted onco-drugs) longer-lasting efficacy, often across many cancer histologies (which translates in large market share potential). However, emerging clinical evidence is showing that only a minority of patients benefits from checkpoint inhibitor monotherapy. Several lines of evidence further suggest that the efficacy of checkpoint inhibitors can be improved by “activation” of the immune system and/or the tumor with other treatments or drugs. This has led to an explosion of opportunistic clinical trials, with drug makers scrambling to find superior combinations of checkpoint inhibitors with their own drugs. However, many combinations suffer from significant and unforeseen toxicities.

THE SOLUTION

MH can help ambitious Pharma companies to ‘jump the queue’ by supporting the trial-and-error efforts with expensive clinical trials with a systematic in silico analysis of the safety and efficacy of their checkpoint combination candidates.

BIOMARKER EXPLORER

THE PROBLEM

Many drugs have been developed for a narrow indication, but may be effective in other disease areas. In some cases, novel efficacy is discovered accidentally in the clinic; in other cases, drug companies deliberately seek to strategically broaden the label to e.g. increase sales or market share.

THE SOLUTION

MH can readily run a project to systematically interrogate any co-perturbations for increased efficacy and/or decreased safety signals compared to focal monotherapies or standard of care.

Request Demo

Insights for healthcare professionals who need them

Labs & Clinicians

Labs & Clinicians

Put more confidence behind patient decisions

Learn More
Hospitals & Research Institutions

Hospitals & Research Institutions

Optimize clinical practice and guidelines to improve care

Learn More
Pharma & Biotech

Pharma & Biotech

Improve drug outcome predictions

Learn More
Regulators

Regulators

Analyze and predict real-world outcomes

Learn More